Cardiac Transplant Rejection

• FDA approval · 2024-08-13
  FDA Approved: MYCOPHENOLATE MOFETIL — Supplemental Application (VistaPharm, LLC)

  FDA approves a supplemental application for mycophenolate mofetil (VistaPharm, LLC), endorsing a generic product for prevention of organ tra…

• FDA approval · 2023-05-09
  FDA Approved: MYCOPHENOLIC ACID — Supplemental Application (Ascend Laboratories, LLC)

  FDA approved Ascend Laboratories' supplemental application for mycophenolic acid, authorizing continued marketing of this generic product.

• FDA approval · 2021-10-22
  FDA Approved: CELLCEPT — Supplemental Application (Genentech, Inc.)

  FDA approves a supplemental application for CELLCEPT (mycophenolate mofetil) submitted by Genentech, Inc.

• FDA approval · 2021-05-04
  FDA Approved: MYCOPHENOLATE MOFETIL — Supplemental Application (Mylan Pharmaceuticals Inc.)

  The FDA approved a supplemental application for mycophenolate mofetil submitted by Mylan Pharmaceuticals, updating labeling and/or indicatio…

• FDA approval · 2021-04-21
  FDA Approved: CELLCEPT — Supplemental Application (Genentech, Inc.)

  FDA approved a supplemental application for CELLCEPT (mycophenolate mofetil) from Genentech, Inc.

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• FDA approval · 2015-10-30
  FDA Approved: MYCOPHENOLATE MOFETIL — Supplemental Application (Mylan Pharmaceuticals Inc.)

  FDA approved a supplemental application for mycophenolate mofetil filed by Mylan Pharmaceuticals Inc. The action relates to the approved gen…

• FDA approval · 2014-01-23
  FDA Approved: CELLCEPT — Supplemental Application (Genentech, Inc.)

  The FDA approved Genentech's supplemental application for Cellcept (mycophenolate mofetil), under NDA 050722, confirming a change/update via…